Business
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
PARIS, October 30, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company’s gene therapy GS010/LUMEVOQ® has been granted regulatory authorizations for an Individual Patient Expanded Access in the United States. The authorizations mark the first set of regula
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/0763a705ed98461906f2d23015b43af7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3IPhXQzJWuV.OZ0oKpGG_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0763a705ed98461906f2d23015b43af7","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA authorization and Institutional Review Board (IRB) approval followed by QP release for expanded access treatment of one patient in the US","length":141,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Treatment scheduled in November 2025 at the University of Pittsburgh School of Medicine","length":87,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Ongoing review of early access dossier by French agency ANSM","length":60,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Technology transfer to new manufacturing partner on track to produce new batches for 2026 milestones","length":100,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":388,"olType":false},{"type":"text","content":"PARIS, October 30, 2025--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company’s gene therapy GS010/LUMEVOQ® has been granted regulatory authorizations for an Individual Patient Expanded Access in the United States. The authorizations mark the first set of regulatory green lights for the candidate product since the Company’s withdrawal of its European marketing authorization application in 2023.","length":593,"tagName":"p"},{"type":"text","content":"FDA authorization was granted for expanded access treatment of one eligible patient, based on an application by a physician at the University of Pittsburgh School of Medicine (UPMC) to the agency. The required approval of the school’s Institutional Review Board (IRB) was also granted. The patient is scheduled ...